| http://www.w3.org/ns/prov#value | - To learn more about this study, including eligibility criteria, please visit www.clinicaltrials.gov.About KaloBiosKaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory disea
|
